Tricol Biomedical is a leader in advanced acute wound care with products that provide rapid Hemostatic Control (HemCon) of bleeding, protection of wounds and promotion of normal healing.

Through research and innovation, the company has delivered a wide range of proprietary and patent protected HemCon® and Mdoc™ branded products for hemostasis to address the varying needs of patients and their healthcare professionals, military medics, paramedics, first responders and consumers.

We work to develop, manufacture and market innovative hemostatic technologies that are safe, effective and time saving across many Pre-Hospital and Hospital specialties.

VISION

Zero preventable deaths due to blood loss with our superior HemCon® & Mdoc™ dressing technologies.

MISSION

Leveraging ever-growing patent protected advanced technology to provide dressings with antibacterial and rapid clotting properties for patients and consumers worldwide suffering from surgical, trauma or wound management.

HISTORY

Tricol Biomedical (formerly HemCon) will proudly celebrate our 20 th anniversary in 2021. The company was established in 2001 on one simple premise: save and improve lives. The Tricol Biomedical HemCon Bandage, released in 2003, was the first advanced dressing to be used on the battlefield for rapid hemorrhage control. In 2016, Tricol Biomedical, Inc. acquired the full hemostatic antibacterial wound care product line of HemCon.

Tricol Biomedical has been a world leader in advanced acute wound care research and development and been dedicated to expanding our technologies, platforms, and applications to improve and save lives around the globe. Through strong scientific background, highly skilled team and significant emphasis on research and development, our initial foundation of advanced hemostatic solutions has now evolved into a global medical products company.

Tricol Biomedical, Inc. is a US company incorporated and headquartered in the State of Oregon.